Psoriatic Arthritis


Only 12% of PsA Patients Say Disease Is Under Control

September 25, 2020

The use of biologics, JAK inhibitors and small molecule medications has become increasingly common for patients with psoriatic arthritis. Findings from the recent Psoriatic Arthritis In America 2020 survey by Health Union shows that of 1,120 patients surveyed, most patients (61 percent) are satisfied with the care they receive from their doctors, but they still struggle with flares and only 12 percent are satisfied with their care plan. In this interview, Brian Green, vice president of community development at Health Union, reviews the results of their latest survey.

The Future of Psoriatic Arthritis Treatment

September 23, 2020

New algorithms and more combination therapeutics are part of the future of psoriatic arthritis care. That’s according to Arthur Kavanaugh, M.D., a rheumatologist with UC San Diego Health who recently presented at the Congress of Clinical Rheumatology East annual meeting held this month.​

JAK1 Inhibitor Filgotinib Meets PsA Safety Profile

September 11, 2020

The investigational JAK inhibitor filgotinib―which is under study as a treatment for a number of rheumatic diseases―has been shown to be safe and well tolerated in psoriatic arthritis patients.

Striking the Right Balance in Psoriatic Arthritis Care

September 10, 2020

Treat-to-target strategies can be effective in addressing rheumatic diseases like psoriatic arthritis, but may not be enough on their own to single-handedly improve quality of life for those living with the disease, write physicians in a new article in Arthritis and Rheumatology.

Diabetes More Common in PsA Than RA

August 06, 2020

Researchers writing in Arthritis Care and Research this week report that rheumatoid arthritis patients actually have a lower rate of type 2 diabetes than people without RA or patients with hypertension, osteoarthritis and psoriatic arthritis.

Guselkumab Approved for Psoriatic Arthritis

July 14, 2020

The U.S. Food and Drug Administration has approved the first IL-23 inhibitor for moderate to severe psoriatic arthritis. The newly approved treatment, guselkumab, has been shown to improve the signs and symptoms of fatigue associated with PsA.

EULAR Report: Ixekizumab Approved for Axial Spondyloarthritis

June 04, 2020

Eli Lilly announced this week that Taltz (ixekizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA). And, this week during the EULAR annual meeting, the company is reporting results from the 52-week SPIRIT phase 3b/4 trial for psoriatic arthritis comparing ixekizumab to adalimumab.

Psoriasis Cancer Prevalence is 4.7% New Research Shows

February 19, 2020

A systematic review and meta-analysis published today in JAMA Dermatology confirms that psoriasis patients have a slightly increased risk of cancer, specifically, keratinocyte cancer and lymphomas.

Apremilast Continues to Show Viability as Monotherapy

January 16, 2020

Psoriatic arthritis patients with moderate disease activity were more likely to reach treatment targets or low disease activity at week 52 with apremilast (Otezla, Celgene) than patients with high disease activity, researchers report in the January 7 issue of Arthritis Care and Research.

Secukinumab Benefits in Psoriatic Arthritis Persist for 5 Years

January 08, 2020

Secukinumab (Cosentyx, Novartis) provided sustained improvements through five years in the signs and symptoms of psoriatic arthritis with no new safety signals, say researchers recently writing in ACR Open Rheumatology.